These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35089797)

  • 1. Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy.
    Laurila PP; Luan P; Wohlwend M; Zanou N; Crisol B; Imamura de Lima T; Goeminne LJE; Gallart-Ayala H; Shong M; Ivanisevic J; Place N; Auwerx J
    Sci Adv; 2022 Jan; 8(4):eabh4423. PubMed ID: 35089797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
    Mordechay S; Smullen S; Evans P; Genin O; Pines M; Halevy O
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy.
    Dubuisson N; Davis-López de Carrizosa MA; Versele R; Selvais CM; Noel L; Van den Bergh PYD; Brichard SM; Abou-Samra M
    Front Immunol; 2022; 13():1049076. PubMed ID: 36569900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
    Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.
    Ponnusamy S; Sullivan RD; You D; Zafar N; He Yang C; Thiyagarajan T; Johnson DL; Barrett ML; Koehler NJ; Star M; Stephenson EJ; Bridges D; Cormier SA; Pfeffer LM; Narayanan R
    Hum Mol Genet; 2017 Jul; 26(13):2526-2540. PubMed ID: 28453658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy.
    Hammers DW; Hart CC; Matheny MK; Wright LA; Armellini M; Barton ER; Sweeney HL
    Sci Rep; 2020 Aug; 10(1):14070. PubMed ID: 32826942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy.
    Verma M; Shimizu-Motohashi Y; Asakura Y; Ennen JP; Bosco J; Zhou Z; Fong GH; Josiah S; Keefe D; Asakura A
    PLoS Genet; 2019 Dec; 15(12):e1008468. PubMed ID: 31877123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbes, metabolites and muscle: Is the gut-muscle axis a plausible therapeutic target in Duchenne muscular dystrophy?
    Marullo AL; O'Halloran KD
    Exp Physiol; 2023 Sep; 108(9):1132-1143. PubMed ID: 37269541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
    Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
    Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas M; Mitchell J
    Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.